Gerald S. Lipshutz, MD, MS, received his medical degree from the University of California Los Angeles (UCLA) School of Medicine and completed his postgraduate training at the University of California San Francisco School of Medicine.  Dr. Lipshutz is a Professor within the Departments of Surgery and the Department of Molecular and Medical Pharmacology. He is also a member of the Intellectual and Developmental Disabilities Institute at UCLA along with the Broad Center; he presently holds the Goldwyn Chair. His research focus is in developing gene and cell therapies for single gene metabolic disorders of the liver. Dr. Lipshutz has been an invited participant in many National Institutes of Health (NIH) conferences and has served as a grant reviewer for both Welcome Trust, UK and the US National Institutes of Health where he recently completed 4 years as a standing member of the GDD Study Section In addition to authoring over 80 peer-reviewed research papers, Dr. Lipshutz also serves on the editorial board for the Molecular Therapy, Molecular Therapy: Methods and Clinical Development, and Gene Therapy. He is a member of several surgical, transplant, and gene and cell therapy societies including ASGCT and SIMD. As a principal investigator at the UCLA Lipshutz Hepatic Regenerative Medical Lab, Dr. Lipshutz’s research focuses on regenerative medicine technologies for the investigation and treatment of urea cycle disorders, specifically arginase deficiency and carbamoyl phosphate synthetase deficiency, and also has a focus in the creatine deficiency disorders. He aims to develop new therapies that would replace liver transplantation for single-enzyme metabolic deficiencies and to understand the neurological effect of arginase deficiency with hyperargininemia. He is also a PI for multiple NIH grants and California Institute of Regenerative Medicine and industry-sponsored studies for gene therapies.